Disease model: Parkinson's disease

Trends in Molecular Medicine

Volumn 9, Issue 8, 2003, Pages 360-365

  Shimohama, Shun ^a   Sawada, Hideyuki ^a   Kitamura, Yoshihisa ^b   Taniguchi, Takashi ^b  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; UBIQUITIN;

CELL INCLUSION; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; ENVIRONMENTAL FACTOR; HEREDITY; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PATHOGENESIS; REVIEW;

EID: 0041926269     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4914(03)00117-5     Document Type: Review

References (62)

1. Lang, E. and Lozano, A.M. (1998) Parkinson's disease. First of two parts. N. Engl. J. Med. 339, 1044-1053
2. Lang, E. and Lozano, A.M. (1998) Parkinson's disease. Second of two parts. N. Engl. J. Med. 339, 1130-1143
3. Dunnett, S.B. and Bjorklund, A. (1999) Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature 399 (Suppl.), A32-A39
4. Olanow, C.W. and Tatton, W.G. (1999) Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. 22, 123-144
5. Mizuno, Y. et al. (1999) Genetics of Parkinson's disease. Biomed. Pharmacother. 53, 109-116
6. Broussolle, E. and Thobois, S. (2002) Genetic and environmental factors of Parkinson's disease. Rev. Neurol. (Paris) 158, 11-23
7. Kruger, R. et al. (2002) Parkinson's disease: one biochemical pathway to fit all genes? Trends Mol. Med. 8, 236-240
8. Gorell, J.M. et al. (1998) The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 50, 1346-1350
9. Menegon, A. et al. (1998) Parkinson's disease, pesticides, and glutathione transferase polymorphisms. Lancet 352, 1344-1346
10. Davis, G.C. et al. (1979) Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res. 1, 249-254
11. Beal, M.F. (2001) Experimental models of Parkinson's disease. Nat. Rev. Neurosci. 2, 325-332
12. Dawson, T.M. (2000) New animal models for Parkinson's disease. Cell 101, 115-118
13. Betarbet, R. et al. (2002) Animal models of Parkinson's disease. Bioessays 24, 308-318
14. Langston, J.W. et al. (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219, 979-980
15. Ballard, P.A. et al. (1985) Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 35, 949-956
16. Kitamura, Y. et al. (2000) The parkinsonian models: invertebrates to mammals. Jpn. J. Pharmacol. 84, 237-243
17. 2-receptor subfamily agonists. Neurochem. Res. 28, 1035-1040
18. Speciale, S.G. (2002) MPTP: insights into parkinsonian neurodegeneration. Neurotoxicol. Teratol. 24, 607-620
19. Kitamura, Y. et al. (1998) Protective effect of talipexole on MPTP-treated planarian, a unique parkinsonian worm model. Jpn. J. Pharmacol. 78, 23-29
20. Kopin, I.J. and Markey, S.P. (1988) MPTP toxicity: implications for research in Parkinson's disease. Annu. Rev. Neurosci. 11, 81-96
21. Langston, J.W. and Irwin, I. (1986) MPTP: current concepts and controversies. Clin. Neuropharmacol. 9, 485-507
22. Hashimoto, M. and Masliah, E. (1999) Alpha-synuclein in lewy body disease and Alzheimer's disease. Brain Pathol. 9, 707-720
23. Jenner, P. (2003) The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease. Parkinsonism Relat. Disord. 9, 131-137
24. Przedborski, S. et al. (2001) The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J. Neurochem. 76, 1265-1274
25. Sedelis, M. et al. (2001) Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav. Brain Res. 125, 109-122
26. + and paraquat in Rana Pipiens. Life Sci. 37, 1529-1539
27. Kitamura, Y. et al. (2003) Inhibitory effects of antiparkinsonian drugs and caspase inhibitors in a parkinsonian flatworm model. J. Pharmacol. Sci. 92, 137-142
28. Ungerstedt, U. (1971) Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol. Scand. 367 (Suppl.), 69-93
29. Deumens, R. et al. (2002) Modeling Parkinson's disease in rats: anevaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp. Neurol. 175, 303-317
30. Betarbet, R. et al. (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3, 1301-1306
31. Sherer, T.B. et al. (2003) Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and α-synuclein aggregation. Exp. Neurol. 179, 9-16
32. Inden, M. et al. Differences in rotational asymmetry in rats caused by single intranigral injections of 6-hydroxydopamine, 1-methyl-4-phenylpyridinium ion and rotenone. Biog. Amines (in press)
33. Jankowsky, J.L. et al. (2002) Transgenic mouse models of neurodegenerative disease: opportunities for therapeutic development. Curr. Neurol. Neurosci. Rep. 2, 457-464
34. Zetterstrom, R.H. et al. (1997) Dopamine neuron agenesis in Nurr1-deficient mice. Science 276, 248-250
35. Zhou, Q-Y. et al. (1995) Targeted disruption of the tyrosine hydroxylase gene reveals that catecholamines are required for mouse fetal development. Nature 374, 640-643
36. Zhou, Q-Y. and Palmiter, R.D. (1995) Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic. Cell 83, 1197-1209
37. Baik, J-H. et al. (1995) parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors. Nature 377, 424-428
38. Xu, M. et al. (1994) Dopamine D1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responses. Cell 79, 729-742
39. Accili, D. et al. (1996) A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc. Natl. Acad. Sci. U. S. A. 93, 1945-1949
40. Vila, M. et al. (2001) Engineered modeling and the secrets of Parkinson's disease. Trends Neurosci. 24 (Suppl.), S49-S55
41. Feany, M.B. and Bender, W.W. (2000) A Drosophila model of Parkinson's disease. Nature 404, 394-398
42. Abeliovich, A. et al. (2000) Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25, 239-252
43. Masliah, E. et al. (2000) Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science 287, 1265-1269
44. Sawada, H. et al. (1996) Mechanisms of resistance to NO-induced neurotoxicity in cultured rat dopaminergic neurons. J. Neurosci. Res. 46, 509-518
45. Kitamura, Y. et al. (1998) Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells. Mol. Pharmacol. 54, 1046-1054
46. Sawada, H. et al. (1996) Different mechanisms of glutamate-induced neuronal death between dopaminergic and non-dopaminergic neurons in rat mesencephalic culture. J. Neurosci. Res. 43, 503-510
47. +) enhances glutamate-induced cytotoxicity against dopaminergic neurons in cultured rat mesencephalon. J. Neurosci. Res. 43, 55-62
48. Perry, T.L. et al. (1982) Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci. Lett. 33, 305-310
49. Kish, S.J. et al. (1985) Glutathione peroxidase activity in Parkinson's disease brain. Neurosci. Lett. 58, 343-346
50. Griffith, O.W. and Meister, A. (1979) Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-buthyl-homocysteine-sulfoximine). J. Biol. Chem. 254, 7558-7560
51. Ibi, M. et al. (1999) Depletion of intracellular glutathione increases susceptibility to nitric oxide in mesencephalic dopaminergic neurons. J. Neurochem. 73, 1696-1703
52. Good, P.F. et al. (1998) Protein nitration in Parkinson's disease. J. Neuropathol. Exp. Neurol. 57, 338-342
53. Ferrante, R.J. et al. (1999) Increased nitrotyrosine immunoreactivity in substantia nigra neurons in MPTP treated baboons is blocked by inhibition of neuronal nitric oxide synthase. Brain Res. 823, 177-182
54. Kitamura, Y. et al. (2002) Antiparkinsonian drugs and their neuroprotective effects. Biol. Pharm. Bull. 25, 284-290
55. Tatton, W.G. et al. (2003) Apoptosis in Parkinson's disease: signals for neuronal degradation. Ann. Neurol. 3 (Suppl.), S61-S72
56. Hartmann, A. et al. (2000) Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 97, 2875-2880
57. Sawada, H. et al. (2000) Neuroprotective mechanism of glial cell line-derived neurotrophic factor in mesencephalic neurons. J. Neurochem. 74, 1175-1184
58. Bauer, R.B. et al. (1982) L-dopa treatment of Parkinson's disease: a ten-year follow up study. J. Am. Geriatr. Soc. 30, 322-325
59. Li, S.C. et al. (1985) A prevalence survey of Parkinson's disease and other movement disorders in the People's Republic of China. Arch. Neurol. 42, 655-657
60. + Parkinson's disease model. Neuropharmacology 42, 1056-1064
61. Sawada, H. et al. (2000) Mechanisms of antiapoptotic effects of estrogens in nigral dopaminergic neurons. FASEB J. 14, 1202-1214
62. Bingaman, K.D. and Bakay, R.A. (2000) The primate model of Parkinson's disease: its usefulness, limitations, and importance in directing future studies. Prog. Brain Res. 127, 267-297